Abstract
The immunosuppressive effects of blood transfusion at surgical operations become manifest as enhanced graft survival, increased cancer recurrence and decreased patient survival, and increased susceptibility to postoperative infections. Blood transfusion in transplant recipients no longer offers this advantage when cyclosporine A is used. The deleterious effects of blood transfusion on the prognosis of some cancers found in the statistical analyses of retrospective studies are considered to be of increasing clinical importance. Therefore, unnecessary blood transfusions should be avoided and special attention directed to the use of autologous blood. Leucocyte-free red blood concentrates are the least immunosuppressive homologous blood preparations. Conventional red blood cell concentrates may also be used in cancer patients until ongoing prospective randomized studies confirm that there is a true association between the use of homologous blood and increased recurrence of cancer.